NCT02115243View on ClinicalTrials.gov

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

PHASE1CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 7, 2015

Study Completion Date

December 7, 2015

Conditions

Unresectable Melanoma

Interventions

DRUG

Ipilimumab

Trial Locations (1)

27707

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER